---
title: "Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292201167.md"
description: "A groundbreaking dual CAR T cell therapy, which targets both CD19 and CD38 proteins, has progressed to Phase 1/2 clinical trials. This innovative approach aims to effectively treat complex autoimmune disorders affecting multiple body systems. The therapy's advancement indicates promising potential for addressing such conditions."
datetime: "2026-07-09T12:31:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292201167.md)
  - [en](https://longbridge.com/en/news/292201167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292201167.md)
generator: "portal-rs"
---

# Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

A groundbreaking dual CAR T cell therapy, which targets both CD19 and CD38 proteins, has progressed to Phase 1/2 clinical trials. This innovative approach aims to effectively treat complex autoimmune disorders affecting multiple body systems. The therapy's advancement indicates promising potential for addressing such conditions.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Related News & Research

- [Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T program](https://longbridge.com/en/news/297902766.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)](https://longbridge.com/en/news/295940831.md)
- [Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE](https://longbridge.com/en/news/295994710.md)
- [Fate Therapeutics starts potentially registrational Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis](https://longbridge.com/en/news/295923904.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**